BX-320 (oral dosing with 200 mg/kg, twice a day for 21 days) shows efficacy in a blood-borne metastasis model. BX-320 inhibits the growth of LOX melanoma tumors in the lungs of nude mice after injection of tumor cells into the tail vein. BX-320 has efficacy in an in vivo tumor model, which may reflect an inhibition of productive implantation of tumor cells in the lung or an inhibition of subsequent tumor growth[1].
| Animal Model: | Athymic (nu/nu) female mice, 6-8 weeks old[1] |
| Dosage: | 200 mg/kg; dose volume was 10 mL/kg |
| Administration: | Oral gavage twice daily (12 h apart) |
| Result: | Significantly inhibited the growth of lung tumors in this model. |
